Adamas Pharmaceuticals Inc. (ADMS) 19.23 $ADMS
Adamas Pharmaceuticals Provides Data Update On ADS-5102 At The American Academy Of Neurology Annual Meeting
PR Newswire - Wed Apr 30, 8:00AM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a specialty pharmaceutical company, today presented data on the safety and efficacy of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a serious movement disorder associated with Parkinson's disease treatment. The data, from Adamas' Phase 2/3 EASED study, included assessments of patients receiving ADS-5102 using a metric called the Clinician's Global Impression of Change (CGI-C). The clinicians were asked to assess their impression of the change in a subject's clinical status related to overall Parkinson's disease, including LID. CGI-C is a tool to evaluate a patient's response over time and is routinely used for a number of diseases, including Parkinson's disease.
Biotech IPOs Hit the Wall
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 28, 5:30PM CDT
While many investors ignore biotechs that have just gone public, waiting for them to mature, you should still keep an eye on the state of the IPO market, since it's a barometer for the risk investors are willing to take with established public...
Adamas Pharmaceuticals Announces Data Update At American Academy Of Neurology Annual Meeting
PR Newswire - Wed Apr 23, 3:00PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a specialty pharmaceutical company, today announced a poster presentation at the American Academy of Neurology (AAN) 66th Annual Meeting, April 26 to May 3, 2014, in Philadelphia, PA.
Adamas Pharmaceuticals Announces Closing of Its Initial Public Offering
PR Newswire - Tue Apr 15, 3:00PM CDT
Adamas Pharmaceuticals, Inc. (Adamas) (Nasdaq:ADMS), a specialty pharmaceutical company, today announced the closing of its initial public offering of 3,000,000 shares of its common stock at a public offering price of $16.00 per share. The shares began trading on The NASDAQ Global Market under the ticker symbol "ADMS" on April 10, 2014. Adamas estimates net proceeds from the offering to be approximately $41.5 million after deducting underwriting discounts and commissions and estimated offering expenses.
Biotech IPOs Adamas, Cerulean Slump In Trading Debut
at Investor's Business Daily - Thu Apr 10, 3:02PM CDT
Adamas Pharmaceuticals (ADMS) and Cerulean Pharma (CERU) launched IPOs Thursday, two of four biotechs expected to debut this week. Adamas priced at 16, the low end of its range. In late afternoon trading, the stock was near 15.30 on the stock market...
Adamas Pharma wavers after IPO raises $48 million
AP - Thu Apr 10, 10:40AM CDT
NEW YORK (AP) — Shares of Adamas Pharmaceuticals wavered Thursday after the drug developer's initial public offering raised $48 million.
Steve Bederman Thought-Technology Leader is Hosting the 2nd in a Webinar Series, "Modernize Your Marketing with the Most Advanced Messaging Solutions in the Marketplace"
PRWeb - Thu Apr 25, 1:07AM CDT
Communication and technology are forever evolving and changing. In the United States alone, approximately 91% of the population has their mobile device within reach 24/7. Additionally, the average user looks at their phone 150 times a day.
Adamas Pharmaceuticals Provides Data Update On ADS-5102 At The American Academy Of Neurology Annual Meeting
PR Newswire - Wed Apr 30, 8:00AM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a specialty pharmaceutical company, today presented data on the safety and efficacy of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a serious movement disorder associated with Parkinson's disease treatment. The data, from Adamas' Phase 2/3 EASED study, included assessments of patients receiving ADS-5102 using a metric called the Clinician's Global Impression of Change (CGI-C). The clinicians were asked to assess their impression of the change in a subject's clinical status related to overall Parkinson's disease, including LID. CGI-C is a tool to evaluate a patient's response over time and is routinely used for a number of diseases, including Parkinson's disease.
Biotech IPOs Hit the Wall
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 28, 5:30PM CDT
While many investors ignore biotechs that have just gone public, waiting for them to mature, you should still keep an eye on the state of the IPO market, since it's a barometer for the risk investors are willing to take with established public...
Adamas Pharmaceuticals Announces Data Update At American Academy Of Neurology Annual Meeting
PR Newswire - Wed Apr 23, 3:00PM CDT
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a specialty pharmaceutical company, today announced a poster presentation at the American Academy of Neurology (AAN) 66th Annual Meeting, April 26 to May 3, 2014, in Philadelphia, PA.
Adamas Pharmaceuticals Announces Closing of Its Initial Public Offering
PR Newswire - Tue Apr 15, 3:00PM CDT
Adamas Pharmaceuticals, Inc. (Adamas) (Nasdaq:ADMS), a specialty pharmaceutical company, today announced the closing of its initial public offering of 3,000,000 shares of its common stock at a public offering price of $16.00 per share. The shares began trading on The NASDAQ Global Market under the ticker symbol "ADMS" on April 10, 2014. Adamas estimates net proceeds from the offering to be approximately $41.5 million after deducting underwriting discounts and commissions and estimated offering expenses.
Biotech IPOs Adamas, Cerulean Slump In Trading Debut
at Investor's Business Daily - Thu Apr 10, 3:02PM CDT
Adamas Pharmaceuticals (ADMS) and Cerulean Pharma (CERU) launched IPOs Thursday, two of four biotechs expected to debut this week. Adamas priced at 16, the low end of its range. In late afternoon trading, the stock was near 15.30 on the stock market...
Adamas Pharma wavers after IPO raises $48 million
AP - Thu Apr 10, 10:40AM CDT
NEW YORK (AP) — Shares of Adamas Pharmaceuticals wavered Thursday after the drug developer's initial public offering raised $48 million.
Steve Bederman Thought-Technology Leader is Hosting the 2nd in a Webinar Series, "Modernize Your Marketing with the Most Advanced Messaging Solutions in the Marketplace"
PRWeb - Thu Apr 25, 1:07AM CDT
Communication and technology are forever evolving and changing. In the United States alone, approximately 91% of the population has their mobile device within reach 24/7. Additionally, the average user looks at their phone 150 times a day.
